Kamada Ltd. (KMDA)

Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kamada (KMDA) could produce exceptional returns because of its solid growth attributes.

The consensus price target hints at an 110.1% upside potential for Kamada (KMDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

KMDA remains a buy as it delivers strong earnings growth, robust cash generation, and trades at a discount to healthcare peers with an attractive FCF yield. Q2 results confirm ongoing operating leverage, with each $1 in new sales producing $3-$5 in incremental operating profit and EBITDA margins above industry averages. Strategic growth pillars—organic expansion and infrastructure investment, including the new FDA-approved plasma center—are driving future revenue and margin optionality.

Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.

Kamada (KMDA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Kamada (KMDA) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Kamada Ltd. (NASDAQ:KMDA ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Amir London - Chief Executive Officer Chaime Orlev - Chief Financial Officer Conference Call Participants Annabel Eva Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division James Philip Sidoti - Sidoti & Company, LLC Brian Ritchie - Lifesci Advisors, LLC Operator Greetings, and welcome to the Kamada Limited Second Quarter 2025 Earnings Conference Call.

The headline numbers for Kamada (KMDA) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kamada (KMDA) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.